You et al. measured the BNP and sST2 levels in 94 patients with pediatric dilated cardiomyopathy and observed an association of sST2 levels with 6-month and long-term adverse events, sST2 being a promising biomarker that is superior for identifying pediatric patients with DCM at high risk, compared with using BNP alone [49]. The gene discussed is NPPB; the disease is dilated cardiomyopathy.